Rilotumumab AMG 102|cas:872514-65-3|西域试剂

Rilotumumab AMG 102,99.10%

产品编号：Bellancom-P99217| CAS NO：872514-65-3

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99217	￥3100.00	杭州北京（现货）
Bellancom-P99217	￥8050.00	杭州北京（现货）
Bellancom-P99217	￥12900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Rilotumumab AMG 102

产品介绍

Rilotumumab (AMG 102) 是一种 anti-HGF (抗肝细胞生长因子) 的单克隆抗体，抑制 HGF/MET 驱动的信号传导。Rilotumumab 具有抗肿瘤活性，可用于去势抵抗性前列腺癌 (CRPC) 和实体瘤的研究。

生物活性

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

体外研究

Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	U87MG.vIII cells
Concentration:	10 μg/mL
Incubation Time:	Overnight
Result:	Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells. Showed an increase in total MET compared with untreated cells.

体内研究
(In Vivo)

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:	Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

体内研究

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:	Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

体内研究

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:	Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).